The medication is FDA-approved for patients with type 2 diabetes, established cardiovascular disease, and those with chronic kidney disease and type 2 diabetes
Semaglutide has demonstrated up to 1520% body weight reduction in clinical settings, significantly outperforming traditional therapies
Wegovy is effective for weight loss and has been proven so in clinical trials, while Ozempic has not been tested specifically for this purpose, although it may help type 2 diabetics lose some weight
The scale finally cooperates
(1991) in freshly isolated cerebral astrocytes and by Rao and Murthy (1993) in isolated cerebellar astrocytes that glutamate oxidation is mainly transaminase-dependent, support the latter conclusion
For someone starting at 200 lbs, the number approaches 48 lbs